Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 3.03, 5.03, 9.01 · 8-K

Medicus Pharma Ltd.

MDCXNASDAQEQUITYCurrent

Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Item 3.03 Material Modification to Rights of Security Holders Medicus Pharma Ltd. (the "Company") effected a 1-for-50 share consolidation (the "Share Consolidation") of the Company's issued and outstanding common shares, no par value (the "Common Shares") by filing Articles of Amendment (the "Articles of Amendment") with the Ontario Ministry of Public and Business Service Delivery on October 12, 2026.…

Filed Oct 16, 2026Accepted Oct 16, 2026, 4:55 PM EDTCIK 1997296Accession 0001062993-26-005382
Share

Company context

We are a clinical-stage, multi-strategy, life science and biotech company focused on investing in and  accelerating the clinical development programs of novel and disruptive therapeutic assets. Currently, we are  developing two products, SkinJectTM ("SkinJectTM"), with an indication for basal cell carcinoma, and Teverelix trifluoroacetate ("Teverelix", and together with SkinJectTM, the "Products").

Current securities

Recent company filings

  1. 425 filingNov 9, 2026
  2. 425 filingNov 6, 2026
  3. 424B3 filingNov 6, 2026
  4. 10-Q filingNov 6, 2026
  5. Regulation FD DisclosureNov 4, 2026

Registered securities in this filing

Medicus Pharma Ltd. · 8-K · Filed 2026-10-16

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common shares, no par value

Symbol
MDCX
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: CR20261012_dei_EntityListingsExchangeAxis_exch_XNCM_us-gaap_StatementClassOfStockAxis_mdcx_CommonSharesNoParValueMember

Dimensions: us-gaap:StatementClassOfStockAxis

Warrants, exercisable for common shares

Symbol
MDCXW
Exchange
NASDAQ
Classification
WARRANT
Status
Current
Filing context

Context: CR20261012_dei_EntityListingsExchangeAxis_exch_XNCM_us-gaap_StatementClassOfStockAxis_mdcx_WarrantsEachExercisableForOneCommonShareAtAnExercisePriceOfFourPointSixFourPerShareMember

Dimensions: us-gaap:StatementClassOfStockAxis

Accession 000106299326005382 · 2 registered-security cover members

Read the exact SEC filing ↗

Disclosure sections

Items 3.03, 5.03, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 3.03Item 3.03 - Material Modification to Rights
Item 3.03 Material Modification to Rights of Security Holders Medicus Pharma Ltd. (the "Company") effected a 1-for-50 share consolidation (the "Share Consolidation") of the Company's issued and outstanding common shares, no par value (the "Common Shares") by filing Articles of Amendment (the "Articles of Amendment") with the Ontario Ministry of Public and Business Service Delivery on October 12, 2026. The Share Consolidation and Articles of Amendment became effective on October 12, 2026 and the Common Shares began trading on a post-Share Consolidation basis on The Nasdaq Capital Market on October 12, 2026. On June 3, 2026, the Company held its Annual General and Special Meeting of Shareholders (the "Meeting"). At the Meeting, the Company's shareholders approved the Share Consolidation for up to a maximum ratio of 1-for-50, such ratio and the implementation and timing of such Share Consolidation to be determined by the Company's board of directors (the "Board") at its sole discretion. On September 24, 2026, the Board unanimously approved the Share Consolidation at a ratio of 1-for-50 Common Shares. As a result of the Share Consolidation, every 50 Common Shares issued and outstanding were automatically consolidated into one new Common Share. The Share Consolidation did not modify any rights or preferences of the Common Shares. Proportionate adjustments were made to the exercise or conversion prices and the number of Common Shares underlying the Company's outstanding equity awards, convertible securities and warrants, as well as to the number of Common Shares issued and issuable under the Company's equity incentive plans. The Common Shares issued pursuant to the Share Consolidation remain fully paid and non-assessable. No fractional shares were issued in connection with the Share Consolidation. Any fractional shares resulting from the Share Consolidation were automatically rounded down to the nearest whole Common Share and cash was paid in lieu for such fractional shares. Ownership percentages did not meaningfully change as a result of rounding down the fractional shares. Similarly, no fractional shares will be issued on the exercise of the Company's outstanding equity awards, convertible securities and warrants, except as otherwise expressly specified in the documents governing such stock options, awards or rights. The foregoing description of the Articles of Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Articles of Amendment, which is filed herewith as Exhibit 3.1 and incorporated herein by reference.
Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. The information set forth in Item 3.03 of this Current Report on Form 8-K with respect to the Articles of Amendment is incorporated by reference into this Item 5.03.

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.